Programs progressing in line with strategy
Significant reduction of net loss: ?12.2 million compared to ?28.1 million in H1 2015
?33.4 million in cash and cash equivalents as of June 30, 2016
Cash burn guidance confirmed around ?35 million in 2016
Conference call scheduled in English on September 6th, 2016 at 06:00 PM CET (12:00 PM EST)
Strasbourg, France, September 5, 2016, 5:35 pm CET - Transgene (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today announced its financial results for the six-month period ended June 30, 2016 and published an update on its business and on the development of its portfolio of therapeutic vaccines and oncolytic viruses.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||2.69 (c)||2.67%||179 214|